By expenditures
| Name | Title | Type |
|---|---|---|
| Ann Malfavon | HCV Coordinator | Auditee |
| Rich Larsen | Partner | Auditee |
| No contacts on file | ||
| ID | Year | Date Accepted | Auditor | Spend |
|---|---|---|---|---|
| 366902 | 2024 | 2025-09-22 | Novogradac & Company LLP | $10.31M |
| 320673 | 2023 | 2024-09-24 | Novogradac & Company LLP | $9.62M |
| Audit | Year | Accepted | Finding | Ref | Severity | Repeat | Requirement |
|---|---|---|---|---|---|---|---|
| 320673 | 2023 | 2024-09-24 | 1074442 | 2023-001 | Material Weakness | - | N |
| 320673 | 2023 | 2024-09-24 | 1074441 | 2023-003 | Material Weakness | - | N |
| 320673 | 2023 | 2024-09-24 | 1074440 | 2023-002 | Material Weakness | - | N |
| 320673 | 2023 | 2024-09-24 | 1074439 | 2023-001 | Significant Deficiency | - | N |
| 320673 | 2023 | 2024-09-24 | 498000 | 2023-001 | Material Weakness | - | N |
| 320673 | 2023 | 2024-09-24 | 497999 | 2023-003 | Material Weakness | - | N |
| 320673 | 2023 | 2024-09-24 | 497998 | 2023-002 | Material Weakness | - | N |
| 320673 | 2023 | 2024-09-24 | 497997 | 2023-001 | Significant Deficiency | - | N |